198 related articles for article (PubMed ID: 31894743)
1. A Computational Study of Natural Compounds from Bacopa monnieri in the Treatment of Alzheimer's Disease.
Jamal QMS; Siddiqui MU; Alharbi AH; Albejaidi F; Akhtar S; Alzohairy MA; Kamal MA; Kesari KK
Curr Pharm Des; 2020; 26(7):790-800. PubMed ID: 31894743
[TBL] [Abstract][Full Text] [Related]
2. Identification of Natural Compounds of the Apple as Inhibitors against Cholinesterase for the Treatment of Alzheimer's Disease: An In Silico Molecular Docking Simulation and ADMET Study.
Jamal QMS; Khan MI; Alharbi AH; Ahmad V; Yadav BS
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049419
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches.
Pang X; Fu H; Yang S; Wang L; Liu AL; Wu S; Du GH
Molecules; 2017 Jul; 22(8):. PubMed ID: 28933746
[TBL] [Abstract][Full Text] [Related]
4. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
[TBL] [Abstract][Full Text] [Related]
5. In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer's disease.
Kumar V; Saha A; Roy K
Comput Biol Chem; 2020 Oct; 88():107355. PubMed ID: 32801088
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
[TBL] [Abstract][Full Text] [Related]
7. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors.
Daoud I; Melkemi N; Salah T; Ghalem S
Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and molecular dynamics approach to identify potential compounds in
Tung BT; Hang TTT; Kim NB; Nhung NH; Linh VK; Thu DK
J Complement Integr Med; 2022 Dec; 19(4):955-965. PubMed ID: 35621378
[TBL] [Abstract][Full Text] [Related]
9. Multi-target approach for Alzheimer's disease treatment: computational biomolecular modeling of cholinesterase enzymes with a novel 4-
Adeowo FY; Ejalonibu MA; Elrashedy AA; Lawal MM; Kumalo HM
J Biomol Struct Dyn; 2021 Jul; 39(11):3825-3841. PubMed ID: 33030113
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and molecular docking studies of 5-trifluoromethoxy-2-indolinones as cholinesterase dual inhibitors.
Soylu-Eter Ö; Özsoy N; Karalı N
Future Med Chem; 2024 Apr; 16(7):623-645. PubMed ID: 38470247
[No Abstract] [Full Text] [Related]
11. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
12. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
13. Bioactivity of hamamelitannin, flavokawain A, and triacetyl resveratrol as natural compounds: Molecular docking study, anticolon cancer, and anti-Alzheimer potentials.
Zhang M; Xue J; Chen X; Elsaid FG; Salem ET; Ghanem RA; El-Kott AF; Xu Z
Biotechnol Appl Biochem; 2023 Apr; 70(2):730-745. PubMed ID: 35933706
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
[TBL] [Abstract][Full Text] [Related]
15. Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer's Disease: An
Liu S; Dang M; Lei Y; Ahmad SS; Khalid M; Kamal MA; Chen L
Curr Pharm Des; 2020; 26(37):4808-4814. PubMed ID: 32264807
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological activity of novel tacrine-isatin Schiff base hybrid derivatives.
Riazimontazer E; Sadeghpour H; Nadri H; Sakhteman A; Tüylü Küçükkılınç T; Miri R; Edraki N
Bioorg Chem; 2019 Aug; 89():103006. PubMed ID: 31158577
[TBL] [Abstract][Full Text] [Related]
17. Search for new multi-target compounds against Alzheimer's disease among histamine H
Bajda M; Łażewska D; Godyń J; Zaręba P; Kuder K; Hagenow S; Łątka K; Stawarska E; Stark H; Kieć-Kononowicz K; Malawska B
Eur J Med Chem; 2020 Jan; 185():111785. PubMed ID: 31669851
[TBL] [Abstract][Full Text] [Related]
18. Computational Analysis of
Sangeet S; Khan A; Mahanta S; Roy N; Das SK; Mohanta YK; Saravanan M; Tag H; Hui PK
Curr Comput Aided Drug Des; 2023; 19(1):24-36. PubMed ID: 36221888
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus
Dos Santos R; Morais-Urano RP; Marçal RM; Silva GH; Santos MFC
Nat Prod Res; 2022 Aug; 36(16):4153-4158. PubMed ID: 34498969
[TBL] [Abstract][Full Text] [Related]
20. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
